Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Non-Dispersive Reaction and Separation Processes for Pharmaceutical Synthesis

    SBC: CHEMTOR, L.P.            Topic: 300

    DESCRIPTION provided by applicant A number of pharmaceutical reactions and wash processes involve interaction between immiscible phases within reactors or extraction equipment Multi phase synthesis processes have been traditionally been carried out through dispersion of one of the phases into the other in the form of droplets Such arrangement increases the surface area of interaction thereby ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. A novel racial disparity marker for risk prediction in triple negative breast cancer patients

    SBC: NOVAZOI THERANOSTICS            Topic: NIMHD

    DESCRIPTION provided by applicant Breast cancers in African American AA women are characterized by earlier onset higher aggressiveness more extensive metastases and increased mortality rates compared to those in European American EA women This breast cancer related health disparity is partly due to the fact that AA women are more likely than EA women to develop a particularly aggressive ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Small Molecules To Inhibit PCSK9-LDLR

    SBC: Small Molecules PPI Mimics, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This proposal is to prepare small molecules that will inhibit the protein protein interaction between a protein called PCSK and the LDLR receptor This is an extremely well validated target for reduction of andquot badandquot cholesterol LDL and therefore controlling coronary artery disease Orally available small molecules are the preferred therapeutic mo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. APPSPIRE: expanding the reach of an innovative tobacco control program for youth

    SBC: Radiant Creative Group, LLC            Topic: NIDA

    DESCRIPTIONprovided by applicantMobile phone technology offers a variety of opportunities for innovative approaches to health communication and interventionThese opportunities have been amplified by the emergence of next generation smartphone devices that are capable of rich multimedia and sophisticated interactivitySmartphone based programs can be integrated seamlessly into a userandapos s daily ...

    STTR Phase II 2015 Department of Health and Human Services
  5. Using game mechanics to improve outcomes among stem cell transplant survivors

    SBC: Radiant Creative Group, LLC            Topic: NCI

    DESCRIPTION provided by applicant Adolescent and young adult AYA hematopoietic stem cell transplantation HSCT patients face a variety of well documented physical and emotional challenges In addition to undergoing a life threatening procedure that involves an intense treatment regimen and lengthy hospital stay these patients face a protracted month recovery period marked by numerous phy ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Triple Re-uptake Inhibitor, SKL 10406, as a New Treatment for Alcohol Dependence

    SBC: Medication Discovery Texas, Inc            Topic: NIAAA

    DESCRIPTION provided by applicant Three medications are approved by the FDA as treatments for alcohol dependence disulfiram acamprosate and naltrexone but these are seldom prescribed due to poor efficacy or side effects Another topiramate is effective for reducing alcohol use but it causes a range of side effects that limit its tolerability Another clas of potentially effective treatment ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Lactoferrin Modulation of Granuloma Pathology

    SBC: PHARMAREVIEW CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant Host immunity plays a major role in development of Tuberculosis disease Tuberculosis infected individuals respond by formation of granulomas which contain bacilli However organisms within granulomas are protected from the full scope of immune mediated defenses We hypothesize that modulation of destructive immune mediated pathology while preserving essent ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Green Algal Strains for Biological Control of West Nile Virus Mosquitoes

    SBC: Pond Life Technologies Limited Liability Company            Topic: NIAID

    DESCRIPTION provided by applicant West Nile virus WNV has become endemic to the US with yearly infection peaks coinciding with the activity of its mosquito vector was the worst year for WNV since with deaths and estimates of non neuroinvasive cases There is no specific treatment or vaccine so mosquito control is the only approach available Fortunately controll ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Broad Spectrum Antiviral for Ebola and Marburg viral Infections

    SBC: Omm Scientific, Inc            Topic: NIAID

    DESCRIPTION provided by applicant The long term goal of this project is to gain FDA approval for commercialization of a broad spectrum small molecule antiviral agent that is effective in treating Ebola virus EBOV and Marburg virus MARV These pathogens are major biothreat agents for which there are no approved therapeutic options or vaccines The developed drug will inhibit a conserved hum ...

    STTR Phase I 2015 Department of Health and Human Services
US Flag An Official Website of the United States Government